APA
Kessler E. R., Gao D., Flaig T. W., Breaker K., Wold M., Wacker M. & Lam E. T. (20180118). Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. : Annals of oncology : official journal of the European Society for Medical Oncology.
Chicago
Kessler E R, Gao D, Flaig T W, Breaker K, Wold M, Wacker M and Lam E T. 20180118. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. : Annals of oncology : official journal of the European Society for Medical Oncology.
Harvard
Kessler E. R., Gao D., Flaig T. W., Breaker K., Wold M., Wacker M. and Lam E. T. (20180118). Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. : Annals of oncology : official journal of the European Society for Medical Oncology.
MLA
Kessler E R, Gao D, Flaig T W, Breaker K, Wold M, Wacker M and Lam E T. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. : Annals of oncology : official journal of the European Society for Medical Oncology. 20180118.